Vaxcyte. has been granted a patent for methods to produce immunogenic compositions using non-natural amino acids. These compositions feature crosslinked carrier protein-antigen conjugates targeting various serotypes of Streptococcus pneumoniae, enhancing antigen presentation and purification through bio-orthogonal attachment chemistry. GlobalData’s report on Vaxcyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Vaxcyte, LPS antibody-based anti-bacterials was a key innovation area identified from patents. Vaxcyte's grant share as of June 2024 was 4%. Grant share is based on the ratio of number of grants to total number of patents.
Immunogenic compositions with non-natural amino acid conjugates
The granted patent US11998599B2 describes a novel composition consisting of at least 21 distinct crosslinked carrier protein-antigen conjugates. Each conjugate features an antigen derived from a unique serotype of capsular polysaccharide antigen from Streptococcus pneumoniae. The patent specifies that there is a distinct conjugate for each of the serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, along with at least eight additional serotypes selected from a defined group. The carrier protein in these conjugates includes a polypeptide with at least one T-cell activating epitope and a high degree of sequence identity to a specified sequence, incorporating a non-natural amino acid at designated residues.
Further claims within the patent elaborate on the composition's flexibility, allowing for variations in the number of distinct conjugates, including those that cover additional serotypes such as 2, 6C, 8, and others. The patent also details the structural linkage of the antigens to the carrier proteins, specifying ratios of serotype polysaccharides to carrier protein, and limits on the presence of free capsular polysaccharides. The inclusion of specific serotypes, such as 20B, and the potential for additional conjugates for serotypes 6C or 7C, are also highlighted, indicating a comprehensive approach to developing a robust immunogenic composition targeting multiple serotypes of Streptococcus pneumoniae.
To know more about GlobalData’s detailed insights on Vaxcyte, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
